Evidence map›Paper›PMID 40535070›Full record

ArticleTranslational lung cancer research2025

Construction of a checkpoint inhibitor-related pneumonia diagnostic model based on exhaled nitric oxide: a prospective observational study.

Yimei Gao, Tingyue Luo, Danhui Huang, Zeyu Fu, Shudong Ma, Li Lin, Haohua Huang, Tiantian Liu, Jinming Zhang, Xiaoxiao Jiang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yimei Gao *Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Tingyue Luo *Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Danhui Huang *Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zeyu FuChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Shudong MaDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Li LinDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Haohua HuangChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Tiantian LiuChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jinming ZhangChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaoxiao JiangChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yanmei YeChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Junwei ChenChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Junjie XiChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jinzhong ZhuoChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Kaijun ChenChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jingqi AiChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Laiyu LiuChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Shaoxi CaiChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hangming DongChronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Checkpoint inhibitor-related pneumonia (CIP) is a complication of immune checkpoint inhibitors (ICIs) with high mortality. There is still a lack of effective biomarkers to identify CIP. Exhaled nitric oxide (eNO), an airway inflammatory marker, can be obtained by non-invasive methods, but its value in CIP is unknown. The purpose of this study was to investigate the value of eNO in CIP. Methods: Lung cancer patients who received ICIs were included at Nanfang Hospital, Southern Medical University. Fractional eNO at expiratory flow rates of 50 and 200 mL/s (FeNO50 and FeNO200) were measured. The alveolar concentration of nitric oxide (CaNO) was calculated based on the two-compartment model of airway and alveoli. The optimal CaNO cut-off value was determined by the receiver operating characteristic (ROC) curve. eNO, clinical characteristics, and laboratory tests were analyzed to find out the risk factors for CIP by logistic regression analysis. A multi-indicator model based on best risk factors for CIP was developed and internally validated. Results: CaNO was significantly elevated in the CIP group [8.1±5.0 Conclusions: CaNO may be a new marker for identifying CIP. Increased CaNO, pre-existing radiotherapy and emphysema reported on chest CT, a small amount of pleural effusion reported on chest CT, and lower count of lymphocyte cell in peripheral blood are independently associated with CIP.

Indexed as

checkpoint inhibitor-related pneumonia (CIP)diagnostic modelexhaled nitric oxide (eNO)Lung cancer

Identifiers

PMID40535070
PMCPMC12170240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.